PRMT6 and hepatocellular carcinoma: In HCC, PRMT6 methylates CRAF at R100, inhibiting its interaction with RAS and attenuating MEK/ERK signaling, thereby downregulating CD133, SOX2, and Nanog and reducing stemness [506].